A Phase 1/2, Randomized, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50 Through 85 Years Of Age
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 19 Dec 2018
At a glance
- Drugs Pneumococcal vaccine conjugate (Primary) ; DTaP vaccine
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors Pfizer
- 11 Jul 2018 Planned End Date changed from 28 May 2019 to 24 May 2019.
- 11 Jul 2018 Planned primary completion date changed from 28 May 2019 to 24 May 2019.
- 11 Jul 2018 Status changed from recruiting to active, no longer recruiting.